Angioplasty Balloons

Global Angioplasty Balloons Market to Reach US$3.8 Billion by 2030

The global market for Angioplasty Balloons estimated at US$3.0 Billion in the year 2024, is expected to reach US$3.8 Billion by 2030, growing at a CAGR of 3.9% over the analysis period 2024-2030. Normal Balloons, one of the segments analyzed in the report, is expected to record a 3.9% CAGR and reach US$2.1 Billion by the end of the analysis period. Growth in the Drug-Coated Balloons segment is estimated at 4.1% CAGR over the analysis period.

The U.S. Market is Estimated at US$793.3 Million While China is Forecast to Grow at 5.9% CAGR

The Angioplasty Balloons market in the U.S. is estimated at US$793.3 Million in the year 2024. China, the world`s second largest economy, is forecast to reach a projected market size of US$787.6 Million by the year 2030 trailing a CAGR of 5.9% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 2.6% and 3.0% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 3.1% CAGR.

Global Angioplasty Balloons Market - Key Trends and Drivers Summarized

How Are Angioplasty Balloons Revolutionizing Cardiac Care?

Angioplasty balloons are integral tools in the field of interventional cardiology, playing a pivotal role in the treatment of coronary artery disease (CAD). These devices are used in percutaneous coronary interventions (PCI) to dilate narrowed or blocked coronary arteries, restoring blood flow to the heart muscle and alleviating symptoms such as chest pain and shortness of breath. The procedure involves inserting a catheter with a deflated balloon at its tip into the affected artery. Once positioned, the balloon is inflated to compress the plaque against the artery walls, thereby widening the vessel. The advent of angioplasty balloons has revolutionized cardiac care by offering a minimally invasive alternative to coronary artery bypass grafting (CABG), reducing recovery times and hospital stays for patients.

What Technological Innovations Are Enhancing the Efficacy of Angioplasty Balloons?

Technological advancements have significantly enhanced the efficacy and safety of angioplasty balloons. The development of drug-eluting balloons (DEBs) represents a major innovation, combining mechanical plaque compression with localized drug delivery to prevent restenosis, or re-narrowing of the artery. These balloons are coated with antiproliferative drugs, which are released into the arterial wall during inflation, inhibiting the growth of scar tissue that can lead to restenosis. Additionally, the introduction of cutting and scoring balloons, equipped with tiny blades or scoring elements, provides an improved method for tackling particularly tough or calcified lesions by creating controlled incisions in the plaque. These advancements not only improve the success rates of angioplasty procedures but also reduce the need for repeat interventions, enhancing long-term patient outcomes.

Why Is Patient-Centric Care Vital in the Adoption of Angioplasty Balloons?

Patient-centric care is a critical factor in the adoption and success of angioplasty balloon procedures. With a growing emphasis on personalized medicine, healthcare providers are increasingly focusing on tailoring treatments to individual patient needs and conditions. This approach involves careful assessment of patient-specific factors such as the severity and location of arterial blockages, overall health, and coexisting medical conditions. Enhanced imaging techniques and diagnostic tools enable precise planning and execution of angioplasty procedures, ensuring optimal balloon selection and placement. Moreover, patient education and post-procedural care play a vital role in improving outcomes, as informed patients are more likely to adhere to prescribed medications and lifestyle modifications necessary to maintain artery health. The shift towards a holistic, patient-centric approach in cardiac care not only improves clinical outcomes but also enhances patient satisfaction and quality of life.

What Factors Are Driving Growth in the Angioplasty Balloons Market?

The growth in the angioplasty balloons market is driven by several factors related to technological advancements, end-use applications, and evolving healthcare practices. The increasing prevalence of cardiovascular diseases, particularly coronary artery disease, is a major driver, as the global burden of CAD continues to rise with aging populations and lifestyle-related risk factors. Technological innovations, such as drug-eluting balloons and cutting/scoring balloons, are propelling market growth by improving procedural efficacy and patient outcomes. The shift towards minimally invasive procedures, supported by advancements in catheter-based technologies and imaging modalities, is expanding the use of angioplasty balloons in diverse patient populations. Additionally, the growing emphasis on preventive healthcare and early diagnosis is leading to more frequent use of angioplasty as a first-line treatment for CAD. The expansion of healthcare infrastructure in emerging markets and increased healthcare expenditure are also contributing to market growth, providing greater access to advanced cardiac care technologies. Moreover, the focus on personalized medicine and patient-centric care models is driving demand for tailored angioplasty solutions, further accelerating market expansion.

SCOPE OF STUDY:

The report analyzes the Angioplasty Balloons market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:
Product (Normal Balloons, Drug-Coated Balloons, Other Products); Application (Coronary Angioplasty, Peripheral Angioplasty); End-Use (Hospitals, Ambulatory Surgery Centers, Other End-Uses)

Geographic Regions/Countries:
World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 44 Featured) -

• Abbott Laboratories
• B. Braun Melsungen AG
• BARD, A Becton, Dickinson Company
• Biotronik SE & Co. KG
• Boston Scientific Corporation
• Cardinal Health, Inc.
• Cook Medical LLC
• Endocor GmbH
• Medtronic PLC
• Terumo Corporation
• The Spectranetics Corporation

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.

We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.

As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.

To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!

APRIL 2025: NEGOTIATION PHASE

Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.

JULY 2025 FINAL TARIFF RESET

Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.

Reciprocal and Bilateral Trade & Tariff Impact Analyses:

USA
CHINA
MEXICO
CANADA
EU
JAPAN
INDIA
176 OTHER COUNTRIES.

Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.

Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.